NEW YORK, Sept 22 (Reuters) - Large drug companies have inherent advantages -- including cash to conduct expensive drug studies and to assure survival when trials fail -- that will be increasingly important in coming years, senior executives of Wyeth and Merck and Co said on Tuesday.
